Agentic AI in Pharmacovigilance: Smarter Adverse Event Monitoring

After a drug is approved and released into the market, its safety journey begins anew. Post‑marketing surveillance must track adverse drug reactions (ADRs), emerging side effects, long‑term safety, and real‑world effectiveness across diverse populations. Traditional pharmacovigilance (PV) systemsrelying on voluntary reports, manual case processing, and delayed analysisare struggling to keep pace with the scale and complexity of modern drug use.

Increasingly, PV teams face large volumes of data from electronic health records (EHRs), social media, patient support programmes, scientific literature, and spontaneous reports. Identifying real safety signals from this data tsunami, in time to protect patient health and meet regulatory requirements, has become a major challenge.

Agentic AIa newer class of AI systems capable of autonomous actions, reasoning across data, and continuous adaptationoffers a compelling way to transform PV. By combining data‑processing power with decision‑making capabilities, agentic AI can enhance detection, speed up reporting, and provide scalable, real‑time safety monitoring.

What Is Pharmacovigilance ?

Pharmacovigilance (PV) is the discipline concerned with monitoring the safety of medicines post‑approval, detecting adverse drug reactions (ADRs), and ensuring the continued benefit‑risk balance of pharmaceutical products. It involves collecting reports from patients, healthcare professionals, clinical studies, real‑world data sources, literature, and more.

Traditional PV workflows include case intake, data entry and coding (often using standard dictionaries such as MedDRA), medical review, causality assessment, reporting, and regulatory submissions (e.g. periodic safety update reports, PSURs).

Challenges in conventional PV include:

• Under‑reporting  many ADRs remain unreported.
• Delay  it takes time for reports to be submitted, processed, analysed, and acted upon.
• Data overload  increasing volume and variety of data sources (EHRs, social media, literature).
• Fragmentation  data scattered across systems, manual processes, inconsistent coding standards.
• Regulatory risk  compliance demands, audit requirements, global reporting obligations.

These factors can delay safety signals, affect patient safety, and increase cost and risk for pharmaceutical companies.

What Is Agentic AI ?

Agentic AI refers to AI systems designed not only to analyze data, but to act, decide, and adapt autonomouslyoften orchestrating complex workflows across multiple steps. Rather than simply processing inputs, agentic AI can trigger tasks, manage pipelines, integrate with multiple data sources, and autonomously iterate on outcomes.

In the context of PV, agentic AI can be configured to automatically monitor incoming data streams (e.g. EHRs, patient‑reported data, literature, social media), extract relevant information (names, drug(s), symptoms, outcomes), classify events, assess causality or severity, and trigger alerts or reports. It can function 24/7, scale across geographies and datasets, and rapidly adapt to new regulations or safety protocols.

Compared with traditional AI/ML or signal‑detection tools, agentic AI offers: continuous monitoring, autonomous workflow orchestration, real‑time detection and alerting, cross‑system integration, and the ability to learn and improve over time.

How Agentic AI Improves Pharmacovigilance Workflows

Here is how agentic AI can transform PV operations:

• Automated Data Intake & Processing: Agents ingest data from EHRs, spontaneous reports, social media, patient‑support platforms, literature databases, and other sources. Using natural language processing (NLP) and machine learning (ML), they extract structured information from unstructured text (drug, dose, symptom, date, patient details).
• Signal Detection & Prioritization: AI models analyze data to detect patterns indicative of ADRs or safety signals  for example, a rise in similar symptoms associated with a drug across geographies or demographics. They can apply statistical methods, anomaly detection, or causal‑inference techniques to flag probable issues.
• Real-Time Monitoring & Alerting: Agents can continuously monitor feeds and alert PV or safety‑teams instantly when potential adverse events are detected  enabling timely investigation, safety mitigation, or regulatory reporting.
• Automated Case Processing & Reporting: Once a signal or case is detected, agentic AI can pre‑fill case reports using standardized fields (e.g. using MedDRA codes), prepare regulatory‑compliant reports (e.g. ICSRs, PSURs), and schedule submissions  reducing manual workload and speeding up the reporting cycle.
• Scalable, Multi‑Source Safety Surveillance: Because agents can integrate with multiple data sources and scale horizontally, PV operations can expand beyond traditional reporting to include real‑world data, social media, literature surveillance  improving coverage and detection of rare or long‑term ADRs.
• Risk Assessment & Predictive Safety Analytics: Advanced AI models can predict likelihood of ADRs based on patient demographics, comorbidities, drug combinations  enabling proactive risk management and personalized safety monitoring.

Use Cases

Adverse Event Detection from Text and Real‑World Data

Many ADRs are reported via free‑text sources: EHR notes, patient feedback, social media, forums. Agentic AI, using NLP, can scan massive volumes of unstructured text to extract potential ADRs with semantic understanding  far beyond keyword matching. This increases chances of uncovering previously unreported or rare ADRs.

Signal Detection & Early Safety Alerts

When multiple reports (even if dispersed across geographies or data sources) indicate similar reactions to a drug, traditional PV may take weeks or months to notice. Agentic AI can detect such patterns quickly, highlight potential safety signals, and prompt human review  enabling faster intervention and risk mitigation.

Automated Regulatory Reporting & Compliance

Pharma companies must file regular safety reports (e.g. ICSRs, PSURs) to regulatory authorities. Agentic AI can automate a large part of this process  formatting data, mapping to required fields/dictionaries (like MedDRA), generating reports, and scheduling submissions. This reduces manual effort and ensures timely compliance.

Scalable Global Market Surveillance

For drugs marketed globally, safety monitoring across markets can be challenging due to different reporting systems, languages, and data formats. Agentic AI can unify multi‑region data, normalise it, and provide centralized dashboards, traceability, and compliance tracking  facilitating global PV operations.

Case Study

Context: A multinational pharma company launches a new diabetes drug across 15 countries. Post‑market safety monitoring is critical, especially for ADRs in different demographics. Traditional PV teams expect high volumes of spontaneous reports, delayed submissions, and scattered data.

Agentic‑AI Deployment:

1. An agentic AI pipeline is established to ingest data from multiple sources: EHR feeds (from partner hospitals), patient support call centres, social media monitoring, literature databases, and regional pharmacovigilance systems.
2. NLP and ML layers extract structured ADR cases, code them using MedDRA, assess severity, and classify events (serious / non‑serious).
3. When the volume of similar ADRs crosses a threshold (e.g. unusual clustering in a demographic or region), the system auto‑flags a safety signal, creates a draft Individual Case Safety Report (ICSR), and alerts the global safety team.
4. A dashboard displays real‑time metrics: number of ADRs reported, geographic distribution, severity levels, probable risk clusters. Regulatory‑ready reports are generated automatically at scheduled intervals.

Outcomes

• ADR detection latency reduced from weeks/months to hours.
• Number of identified ADRs increased by 40 percent due to inclusion of non‑traditional sources (social media, call centre logs, etc.).
• Regulatory submissions (ICSRs, periodic safety reports) complied with timelines  avoiding regulatory risk.
• Global safety team achieved real‑time visibility across markets  enabling quicker risk mitigation and recall decisions if needed.

Impact: The company strengthened its safety monitoring while reducing manpower burden, improving compliance, and maintaining global oversight  significantly reducing patient safety risk and regulatory exposure.

Key Benefits

Implementing agentic AI in PV offers major advantages:

• Faster Detection & Response: Real‑time monitoring and alerting enable earlier safety interventions.
• Improved Coverage: Ability to aggregate data from multiple structured and unstructured sources  increasing chances of detecting rare or emerging ADRs.
• Operational Efficiency: Automation of case processing and report generation reduces manual workload, error, and costs.
• Regulatory Compliance & Audit‑Readiness: Standardised coding (e.g. MedDRA), consistent documentation, and traceable audit trails support global regulatory needs.
• Scalability & Global Reach: Agentic AI scales across geographies, languages, and data formats, supporting multinational safety surveillance.
• Proactive Risk Management: Predictive analytics and population‑specific risk modeling help pharma companies anticipate safety issues before they escalate.

Challenges, Risks, and Safeguards

While agentic AI brings substantial value, certain risks and challenges must be addressed:

• Data Quality and Standardization: PV data is often messy, unstructured, or incomplete. AI outcomes depend heavily on data quality and proper preprocessing.
• Explainability and Regulatory Acceptance: Regulatory bodies expect clarity, traceability and human oversight. Black‑box models or hallucinating AI agents pose compliance and safety risks.
• Privacy and Ethics: Handling patient data, sensitive health records, and cross-border data requires strict data protection, consent, and governance.
• Integration and Infrastructure: Combining agentic AI with existing PV systems, databases, EHRs, registries and global reporting systems demands robust architecture and interoperability.
• Human Oversight: AI should augment, not replace, human experts. Final causality assessment, medical review, and regulatory decisions must remain human‑led.

To mitigate these risks, organizations should adopt “AI‑in‑PV best practices”: ensure data hygiene, apply explainable AI (XAI) techniques, maintain audit trails, implement governance and compliance‑by‑design, and enforce human‑in‑the‑loop workflows.

Why 9NEXUS Is an Ideal Partner for Agentic‑AI‑Driven PV Solutions

At 9NEXUS, we combine domain expertise in pharma, regulatory compliance, and AI capabilities. Our offerings include:

• Designing and implementing agentic AI pipelines for PV  data ingestion, NLP/ML modules, signal detection, reporting automation.
• Integrating AI systems with existing PV infrastructure, EHRs, global safety databases, and regulatory submission workflows.
• Building governance frameworks: audit trails, versioning, data privacy, compliance with global regulations.
• Ensuring explainability and human‑in‑the‑loop controls to meet regulatory and ethical guidelines.
• Providing scalable staff augmentation  enabling pharma companies to deploy AI‑powered PV without building large in‑house teams.

With 9NEXUS as your partner, you can adopt next‑gen PV tools faster, stay compliant across markets, and improve drug safety surveillance at scale.

Conclusion

Agentic AI holds transformative potential for pharmacovigilance. By enabling autonomous, continuous, multi‑source monitoring, rapid signal detection, automated case processing, and scalable global surveillance, agentic‑AI‑powered PV systems can significantly enhance drug safety, regulatory compliance, and patient protection.

As data volumes grow and markets become more interconnected, traditional PV methods will struggle to keep pace. Agentic AI offers a path toward smarter, faster, and more comprehensive drug safety monitoring  without compromising compliance or human oversight.

For pharma companies willing to embrace innovation, agentic AI combined with robust governance could redefine how adverse events are detected, reported, and mitigated.